Considering the therapeutic activity of bruton tyrosine kinase (BTK) inhibitors for CNS lymphomas, the patient was administered oral zanubrutinib 80 mg daily (given the concurrent administration of posaconazole for preventing fungal infection) on day +382. This evidence concerns the gene BTK and fungal infectious disease.